EFG Asset Management Americas Corp. Has $243,000 Position in Charles River Laboratories International, Inc. (NYSE:CRL)

EFG Asset Management Americas Corp. lowered its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 11.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,029 shares of the medical research company’s stock after selling 136 shares during the period. EFG Asset Management Americas Corp.’s holdings in Charles River Laboratories International were worth $243,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. VisionPoint Advisory Group LLC boosted its position in shares of Charles River Laboratories International by 105.7% during the third quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company’s stock worth $28,000 after purchasing an additional 74 shares in the last quarter. Headlands Technologies LLC bought a new position in shares of Charles River Laboratories International during the third quarter worth $37,000. Operose Advisors LLC bought a new position in shares of Charles River Laboratories International during the third quarter worth $42,000. Covestor Ltd lifted its position in Charles River Laboratories International by 100.0% in the 1st quarter. Covestor Ltd now owns 174 shares of the medical research company’s stock valued at $49,000 after acquiring an additional 87 shares in the last quarter. Finally, Venturi Wealth Management LLC lifted its position in Charles River Laboratories International by 74.7% in the 3rd quarter. Venturi Wealth Management LLC now owns 262 shares of the medical research company’s stock valued at $51,000 after acquiring an additional 112 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on CRL. Argus boosted their price objective on shares of Charles River Laboratories International from $240.00 to $290.00 and gave the company a “buy” rating in a research report on Monday, March 18th. Citigroup boosted their price objective on shares of Charles River Laboratories International from $215.00 to $250.00 and gave the company a “neutral” rating in a research report on Thursday, February 15th. TheStreet raised shares of Charles River Laboratories International from a “c+” rating to a “b-” rating in a research report on Friday, March 1st. Evercore ISI boosted their price objective on shares of Charles River Laboratories International from $260.00 to $265.00 and gave the company an “outperform” rating in a research report on Thursday, February 15th. Finally, Guggenheim cut shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating in a research report on Thursday, February 15th. Five research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, Charles River Laboratories International currently has a consensus rating of “Moderate Buy” and an average target price of $253.23.

Insider Transactions at Charles River Laboratories International

In other news, VP William D. Barbo sold 4,050 shares of the business’s stock in a transaction dated Thursday, February 22nd. The shares were sold at an average price of $248.50, for a total transaction of $1,006,425.00. Following the transaction, the vice president now directly owns 22,879 shares in the company, valued at approximately $5,685,431.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, EVP Victoria L. Creamer sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $253.70, for a total value of $1,268,500.00. Following the transaction, the executive vice president now owns 13,550 shares of the company’s stock, valued at $3,437,635. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP William D. Barbo sold 4,050 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $248.50, for a total value of $1,006,425.00. Following the sale, the vice president now directly owns 22,879 shares of the company’s stock, valued at $5,685,431.50. The disclosure for this sale can be found here. Insiders have sold 14,932 shares of company stock worth $3,693,663 in the last ninety days. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International Stock Down 0.3 %

Charles River Laboratories International stock opened at $226.78 on Monday. The firm has a market capitalization of $11.68 billion, a PE ratio of 24.62, a P/E/G ratio of 1.78 and a beta of 1.40. The company’s 50-day moving average is $253.73 and its 200-day moving average is $221.62. Charles River Laboratories International, Inc. has a fifty-two week low of $161.65 and a fifty-two week high of $275.00. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.52 and a quick ratio of 1.16.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.46 earnings per share for the quarter, topping the consensus estimate of $2.39 by $0.07. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $991.25 million. Charles River Laboratories International had a net margin of 11.49% and a return on equity of 16.53%. Charles River Laboratories International’s revenue for the quarter was down 7.9% compared to the same quarter last year. During the same period in the previous year, the business earned $2.98 EPS. Sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 11.01 earnings per share for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).